Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 27, 2022 16:01 ET
|
Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...